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 Biosimilar switching and related medical liability. 
 
Abstract  
Unlike generics, biosimilars are similar, but not equivalent, to the reference biological medicinal 
product. Therefore, if a patient experiences an adverse event, or a loss of efficacy, when transitioned to 
a biosimilar, the distribution of medical liability will be different from the case of both the originator and 
generics. Moreover, the case of naïve patients is different from that of non-naïve patients. In the case of 
naïve patients, physicians make their choice from a range of medicinal products that pose the same risk, 
since it is not possible to know with any certainty the patients’ response to each therapeutic option until 
they have taken the drug. If physicians, instead, switch to a biosimilar for a patient already in treatment 
with the originator, they are switching from an option where the individual response is known, to an 
option where it is unknown. 
 
Given the evolving framework of biosimilar legislation, sharing choices with patients and 
obtaining their informed consent when switching to a biosimilar could represent an effective approach 
on the part of the prescribing physician. Moreover, a supranational database containing real-life data 
about patients in treatment with biological medicines, including information on the actual biological 
medicinal products administered, could complement the data obtained from clinical studies. 
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 Introduction 
  
A biosimilar is a medicinal product that is highly similar, but not equivalent, to an already 
approved biological medicine, so-called originator [1, 2]. Therefore, if a patient experiences an adverse 
event, or a loss of efficacy, the distribution of liability will be different from the case of both the originator 
and generics. When an adverse event to a medicinal product is experienced by a patient, we can imagine 
that a chain liability starts, potentially implicating the health professionals involved in the prescription, 
dispensing and administration of the product on the one hand (professional liability), and the 
manufacturers and/or Marketing Authorization holder on the other (products liability). 
 
Products liability 
 
According to US jurisprudence, a medicinal product is defective if, at the time of sale: (1) it 
contains a manufacturing defect (i.e. the product departs from its intended design), or (2) it is not 
reasonably safe due to defective design, or (3) it is not reasonably safe due to inadequate instructions or 
warnings (failure to warn) [3]. 
 
As for manufacturing defects, it is difficult to decide when biological products departs from their 
intended design, due to their inherent variability. Moreover, the complexity of the manufacturing process 
of biological medicines blurs the boundary between manufacturing and design defects. Therefore, the 
Marketing Authorization holder of a biosimilar may hold potential liability for both manufacturing and 
design defects, unlike the case of generics, where those boundaries are clear.  
 
A potential failure to warn liability is not usually ascribable to the generic’s Marketing 
Authorization holder, as confirmed by the US Supreme Court in 2011 in Pliva v. Mensing (564 U.S. 
 604), since the generic product bears the same labelling as the originator [4]. In the case of biosimilars, 
instead, the label is not necessarily identical, therefore the Marketing Authorization holder of the 
biosimilar may be considered responsible if the label fails to provide adequate warning.  
 
Professional liability 
 
The publication of the results from NOR-SWITCH, a randomised, non-inferiority, double-blind, 
phase 4 trial addressing the issue of switching from the originator infliximab to a biosimilar in stable 
patients [5], finally shed some light on a highly debated topic. The conclusions of the study can be seen 
as reassuring for prescribing physicians, at least in the case of infliximab. However, the issue of medical 
liability associated with the switch from the originator to a biosimilar is still far from being explored.  
 
Of the possible causes of  medical liability, the aspects  related to interchangeability and 
substitution play a crucial role in the case of biological medicines, since other issues - such as diagnosis, 
prescription or dispensing errors – concern other medicinal products, as well.  
 
Interchangeability and substitution 
 
Interchangeability is a scientific concept, related to intrinsic drug characteristics, which follows 
from therapeutic equivalence [2, 6]. The term ‘substitution’ instead can have different meanings. It could 
mean either a substitution that occurs under the physician's responsibility, or automatic substitution. 
Automatic substitution occurs at the dispensing level, without the physician’s explicit prior consent, and 
it can be introduced by local authorities on the basis of interchangeability. In the case of biosimilars, 
however, it is usually not allowed [7]. 
  
Substitution performed by the prescribing physician is always possible, though it can take three 
forms with different implications: (1) the prescription of a biosimilar to naïve patients, (2) the switch 
from the originator to a biosimilar, (3) the prescription of a biosimilar, to naïve or non-naïve patients, 
due to payer's policies (non-medical switching or constrained prescription).   
 
Potential sources of professional liability 
 
In the case of naïve patients, physicians make their choice from a range of medicinal products 
that pose the same risk, since it is not possible to know with any certainty the patients’ response to each 
therapeutic option until they have taken the drug. If physicians, instead, switch to a biosimilar for a patient 
already in treatment with the originator, they are switching from an option where the individual response 
is known, to an option where it is unknown. Indeed, given that the production of biosimilars entails a 
variation in the manufacturing process compared to the originator, the use of biosimilars can lead to an 
exposure to different risks for the patient, even though the comparability exercise performed to obtain 
the Marketing Authorization is designed to demonstrate that the biosimilar has the same quality, safety 
and efficacy as the originator. Even when they are produced by the same manufacturer, all 
biopharmaceuticals show an inherent variability. However, the product resulting from batch-to-batch 
variability should not be considered a biosimilar, from a regulatory point of view, since the manufacturer 
has all the data needed to keep the production within accepted and pre-defined limits. [2]. 
 
When the prescription of a biosimilar arises from payer's binding policies, it is not substitution in 
the proper sense, and, if it constitutes an administrative limit to the prescriber's freedom, it is called 
 differently, for example, non-medical switching or constrained prescription [7].  In this case, the issue of 
liability is more complex and the outcome of potential litigations is still very uncertain.  
 
Nonetheless, where there is no real obligation to switch, but only a “recommendation” (think of 
administrative directives within the organization that the physician belongs to), or a “bureaucratic” 
limitation that is non-binding for the physician (think of a hospital medicines handbook which contains 
a more limited list of medicines compared to the national handbook), the physician would be the only 
person responsible for the therapeutic prescription. In most Countries, the physician could continue to 
choose – if necessary giving their justification and whenever they considered it necessary – the 
medicament which they considered the most suitable. Any economic grounds invoked to justify the 
different choice could even be considered conduct dictated by the desire to please the organization they 
belong to and its executives, for the purposes of possible personal recognition and professional 
advancement.  
 
Likewise, any recommendations, guidelines, concept papers, or other documents issued by the 
regulatory authorities, given the emerging technical and scientific uncertainties regarding new 
medicaments, albeit not having any coercive power (since bereft of any sanctions), could tacitly affect 
the exercise of the medical choice due to their persuasive character. Thus, it could happen that the 
physician is induced to follow such indications even when their medical and scientific knowledge would 
lead them in reality to make different choices. In these cases, the responsibility for the therapeutic choice 
would always remain with the physician and, in the case of harm to the patient, the existence of the 
aforementioned documents would not be an absolving factor since they are not binding. 
 
 Biosimilar switching and informed consent 
 
Given the difficulties linked to clinical and scientific assessments, and the possible influence 
dictated by the difference in costs between originators and biosimilars, the informed consent of the patient 
becomes increasingly fundamental to certify that the therapeutic choice has been made through a process 
of sharing information between the physician and the patient. This process should take place with a view 
to collaboration and personalization, as part of which the physician provides the patient, in a correct, 
complete and understandable fashion, all the information needed to allow the latter to fully express their 
right to self-determination, thus sharing in the physician’s choice regarding the medicament. The consent, 
though, could be considered implied by the acceptance of the switch or substitution on the part of the 
patient.  
 
Conclusions 
 
In the USA, the Food and Drug Administration has addressed the issue of interchangeability of 
biosimilars, by providing that interchangeability can be demonstrated [1] (though none of the approved 
biosimilars are deemed interchangeable) and the Administration is supporting a medical tort reform with 
the aim of “reducing the excessive burden the liability system places on the health care delivery system” 
[8]. In Europe, instead, the European Medicines Agency leaves the decision about interchangeability to 
individual member states [7], and the project of harmonising national tort legislations is still in its infancy 
[9]. 
 
In this framework of evolving legislation, sharing choices with patients and obtaining their 
informed consent when switching to a biosimilar could represent an effective approach on the part of the 
 prescribing physician. Moreover, a supranational database containing real-life data about patients in 
treatment with biological medicines, including information on the actual biological medicinal products 
administered could complement existing clinical studies [10].  
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